Skip to main content
Erschienen in: Journal of Neurology 2/2016

01.02.2016 | Original Communication

Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up

verfasst von: L. Piccolo, M. Woodhall, G. Tackley, M. Juryńczyk, Y. Kong, J. Domingos, R. Gore, A. Vincent, P. Waters, M. I. Leite, J. Palace

Erschienen in: Journal of Neurology | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Severe, recurrent or bilateral optic neuritis (ON) often falls within the neuromyelitis optica spectrum disorders (NMOSD), but the diagnosis can be particularly challenging and has important treatment implications. We report the features, course and outcomes of patients presenting with atypical ON when isolated at onset. We retrospectively analyzed 69 sequential patients referred to a single UK NMO center with isolated ON at onset. Aquaporin-4 antibody (AQP4-Ab) assessment was performed in all patients and IgG1 myelin-oligodenrocyte glycoprotein (MOG-Ab) in AQP4-Abneg patients. 37 AQP4-Ab positive (AQP4-Abpos) and 32 AQP4-Ab negative (AQP4-Ab neg) patients (8 with MOG-Ab) were identified. The AQP4-Abneg group included heterogeneous diagnoses: multiple sclerosis (MS), NMO, relapsing isolated ON (RION), monophasic isolated ON and relapsing acute disseminated encephalomyelitis (ADEM)-like syndromes. Compared to AQP4-Abneg patients, AQP4-Abpos patients had a worse residual visual outcome from first attack (median VFSS 4 vs. 0, p = 0.010) and at last assessment (median VFSS 5 versus 2, p = 0.005). However, AQP4-Abneg patients with RION also had poor visual outcome. Up to 35 % of AQP4-Abneg patients developed a LETM and two developed low positivity for AQP4-Ab over time. Eight AQP4-Abneg patients (25 %) were MOG-Ab positive, covering a range of phenotypes excluding MS; the first ON attack was often bilateral and most had relapsing disease with a poor final visual outcome [VFSS 4, range (0–6)]. In conlcusion, AQP4-Ab positivity is confirmed as a predictor of poor visual outcome but AQP4-Abneg RION also had a poor visual outcome. Of those without AQP4-Ab, 25 % had MOG-Ab and another 25 % developed MS; thus, MOG-Ab is associated with AQP4-Abneg non-MS ON.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114CrossRefPubMed Wingerchuk DM, Hogancamp WF, O’Brien PC, Weinshenker BG (1999) The clinical course of neuromyelitis optica (Devic’s syndrome). Neurology 53(5):1107–1114CrossRefPubMed
2.
Zurück zum Zitat Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4water channel. J Exp Med 202(4):473–477CrossRefPubMedPubMedCentral Lennon VA, Kryzer TJ, Pittock SJ, Verkman AS, Hinson SR (2005) IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4water channel. J Exp Med 202(4):473–477CrossRefPubMedPubMedCentral
3.
Zurück zum Zitat Fujihara K, Misu T, Nakashima I et al (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3:58–73CrossRef Fujihara K, Misu T, Nakashima I et al (2012) Neuromyelitis optica should be classified as an astrocytopathic disease rather than a demyelinating disease. Clin Exp Neuroimmunol 3:58–73CrossRef
4.
Zurück zum Zitat Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815CrossRefPubMed Wingerchuk DM, Lennon VA, Lucchinetti CF, Pittock SJ, Weinshenker BG (2007) The spectrum of neuromyelitis optica. Lancet Neurol 6(9):805–815CrossRefPubMed
5.
Zurück zum Zitat Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1–2):158–162CrossRefPubMed Jarius S, Frederikson J, Waters P et al (2010) Frequency and prognostic impact of antibodies to aquaporin-4 in patients with optic neuritis. J Neurol Sci 298(1–2):158–162CrossRefPubMed
6.
Zurück zum Zitat Jacob A, McKeon A, Nakashima I et al (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84(8):922–930CrossRefPubMed Jacob A, McKeon A, Nakashima I et al (2013) Current concept of neuromyelitis optica (NMO) and NMO spectrum disorders. J Neurol Neurosurg Psychiatry 84(8):922–930CrossRefPubMed
7.
Zurück zum Zitat Arrambide G, Rovira A, Tur C, Montalban X (2014) NMO spectrum disorders: how wide is the spectrum? Mult Scler 20(10):1417–1419CrossRefPubMed Arrambide G, Rovira A, Tur C, Montalban X (2014) NMO spectrum disorders: how wide is the spectrum? Mult Scler 20(10):1417–1419CrossRefPubMed
8.
Zurück zum Zitat Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63(7):964–968CrossRefPubMed Pittock SJ, Weinshenker BG, Lucchinetti CF et al (2006) Neuromyelitis optica brain lesions localized at sites of high aquaporin 4 expression. Arch Neurol 63(7):964–968CrossRefPubMed
9.
Zurück zum Zitat Poppe AY, Lapierre Y, Melançon D et al (2005) Neuromyelitis optica with hypothalamic involvement. Mult Scler 11(5):617–621CrossRefPubMed Poppe AY, Lapierre Y, Melançon D et al (2005) Neuromyelitis optica with hypothalamic involvement. Mult Scler 11(5):617–621CrossRefPubMed
10.
Zurück zum Zitat Takahashi T, Fujihara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130(pt 5):1235–1243CrossRefPubMed Takahashi T, Fujihara K, Nakashima I et al (2007) Anti-aquaporin-4 antibody is involved in the pathogenesis of NMO: a study on antibody titre. Brain 130(pt 5):1235–1243CrossRefPubMed
11.
Zurück zum Zitat Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65(7):913–919CrossRefPubMed Waters P, Jarius S, Littleton E et al (2008) Aquaporin-4 antibodies in neuromyelitis optica and longitudinally extensive transverse myelitis. Arch Neurol 65(7):913–919CrossRefPubMed
12.
Zurück zum Zitat Waters PJ, McKeon A, Leite MI et al (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671 (discussion 669. 6) CrossRefPubMedPubMedCentral Waters PJ, McKeon A, Leite MI et al (2012) Serologic diagnosis of NMO: a multicenter comparison of aquaporin-4-IgG assays. Neurology 78(9):665–671 (discussion 669. 6) CrossRefPubMedPubMedCentral
13.
Zurück zum Zitat Kitley J, Leite MI, Küker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 70(11):1375–1381CrossRefPubMed Kitley J, Leite MI, Küker W et al (2013) Longitudinally extensive transverse myelitis with and without aquaporin 4 antibodies. JAMA Neurol 70(11):1375–1381CrossRefPubMed
14.
Zurück zum Zitat Pandit L, Asgari N, Apiwattanakul M et al (2015) Demographic and clinical features of neuromyelitis optica: a review. Multi Scler J 21(7):845–853 (Review) CrossRef Pandit L, Asgari N, Apiwattanakul M et al (2015) Demographic and clinical features of neuromyelitis optica: a review. Multi Scler J 21(7):845–853 (Review) CrossRef
15.
Zurück zum Zitat Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed Kurtzke JF (1983) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 33(11):1444–1452CrossRefPubMed
16.
Zurück zum Zitat Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277CrossRefPubMed Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277CrossRefPubMed
17.
Zurück zum Zitat Waters P, Woodhall M, O’Connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2(3):e89CrossRefPubMedPubMedCentral Waters P, Woodhall M, O’Connor KC et al (2015) MOG cell-based assay detects non-MS patients with inflammatory neurologic disease. Neurol Neuroimmunol Neuroinflamm 2(3):e89CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489CrossRefPubMed Wingerchuk DM, Lennon VA, Pittock SJ, Lucchinetti CF, Weinshenker BG (2006) Revised diagnostic criteria for neuromyelitis optica. Neurology 66(10):1485–1489CrossRefPubMed
19.
Zurück zum Zitat Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70(23):2197–2200 (epub 2008 Apr 23) CrossRefPubMed Matiello M, Lennon VA, Jacob A et al (2008) NMO-IgG predicts the outcome of recurrent optic neuritis. Neurology 70(23):2197–2200 (epub 2008 Apr 23) CrossRefPubMed
20.
Zurück zum Zitat Petzold A, Plant GT (2014) Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev 13(4–5):539–545 (epub 2014 Jan 12) CrossRefPubMed Petzold A, Plant GT (2014) Diagnosis and classification of autoimmune optic neuropathy. Autoimmun Rev 13(4–5):539–545 (epub 2014 Jan 12) CrossRefPubMed
21.
Zurück zum Zitat Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115(6):1079–1082 (e5) CrossRef Optic Neuritis Study Group (2008) Visual function 15 years after optic neuritis: a final follow-up report from the optic neuritis treatment trial. Ophthalmology 115(6):1079–1082 (e5) CrossRef
22.
Zurück zum Zitat Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261(1):17–26CrossRefPubMed Petzold A, Plant GT (2014) Chronic relapsing inflammatory optic neuropathy: a systematic review of 122 cases reported. J Neurol 261(1):17–26CrossRefPubMed
23.
Zurück zum Zitat Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834–1849CrossRefPubMed Kitley J, Leite MI, Nakashima I et al (2012) Prognostic factors and disease course in aquaporin-4 antibody-positive patients with neuromyelitis optica spectrum disorder from the United Kingdom and Japan. Brain 135:1834–1849CrossRefPubMed
24.
Zurück zum Zitat Reindl M, Di Pauli F, Rostásy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9(8):455–461 (Review) CrossRefPubMed Reindl M, Di Pauli F, Rostásy K, Berger T (2013) The spectrum of MOG autoantibody-associated demyelinating diseases. Nat Rev Neurol 9(8):455–461 (Review) CrossRefPubMed
25.
Zurück zum Zitat O’Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211–217CrossRefPubMedPubMedCentral O’Connor KC, McLaughlin KA, De Jager PL et al (2007) Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat Med 13:211–217CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277CrossRefPubMed Kitley J, Woodhall M, Waters P et al (2012) Myelin-oligodendrocyte glycoprotein antibodies in adults with a neuromyelitis optica phenotype. Neurology 79(12):1273–1277CrossRefPubMed
27.
Zurück zum Zitat Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283CrossRefPubMed Kitley J, Waters P, Woodhall M et al (2014) Neuromyelitis optica spectrum disorders with aquaporin-4 and myelin-oligodendrocyte glycoprotein antibodies: a comparative study. JAMA Neurol 71(3):276–283CrossRefPubMed
28.
Zurück zum Zitat Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481CrossRefPubMedPubMedCentral Sato DK, Callegaro D, Lana-Peixoto MA et al (2014) Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders. Neurology 82(6):474–481CrossRefPubMedPubMedCentral
29.
Zurück zum Zitat Ramanathan S, Reddel SW, Henderson A et al (2014) Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1(4):e40CrossRefPubMedPubMedCentral Ramanathan S, Reddel SW, Henderson A et al (2014) Antibodies to myelin oligodendrocyte glycoprotein in bilateral and recurrent optic neuritis. Neurol Neuroimmunol Neuroinflamm 1(4):e40CrossRefPubMedPubMedCentral
30.
Zurück zum Zitat Martinez-Hernandez E, Sepulveda M, Rostásy K et al (2015) Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 72(2):187–193CrossRefPubMedPubMedCentral Martinez-Hernandez E, Sepulveda M, Rostásy K et al (2015) Antibodies to aquaporin 4, myelin-oligodendrocyte glycoprotein, and the glycine receptor α1 subunit in patients with isolated optic neuritis. JAMA Neurol 72(2):187–193CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Brilot F, Dale RC, Selter RC et al (2009) Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66:833–842CrossRefPubMed Brilot F, Dale RC, Selter RC et al (2009) Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann Neurol 66:833–842CrossRefPubMed
32.
Zurück zum Zitat Probstel AK, Dornmair K, Bittner R et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580–588CrossRefPubMed Probstel AK, Dornmair K, Bittner R et al (2011) Antibodies to MOG are transient in childhood acute disseminated encephalomyelitis. Neurology 77:580–588CrossRefPubMed
33.
Zurück zum Zitat Baumann M, Sahin K, Lechner C et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr (epub 2014 Aug 13) Baumann M, Sahin K, Lechner C et al. Clinical and neuroradiological differences of paediatric acute disseminating encephalomyelitis with and without antibodies to the myelin oligodendrocyte glycoprotein. J Neurol Neurosurg Psychiatr (epub 2014 Aug 13)
34.
Zurück zum Zitat Höftberger R, Sepulveda M, Armangue T et al (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21(7):866–874CrossRefPubMed Höftberger R, Sepulveda M, Armangue T et al (2015) Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease. Mult Scler 21(7):866–874CrossRefPubMed
Metadaten
Titel
Isolated new onset ‘atypical’ optic neuritis in the NMO clinic: serum antibodies, prognoses and diagnoses at follow-up
verfasst von
L. Piccolo
M. Woodhall
G. Tackley
M. Juryńczyk
Y. Kong
J. Domingos
R. Gore
A. Vincent
P. Waters
M. I. Leite
J. Palace
Publikationsdatum
01.02.2016
Verlag
Springer Berlin Heidelberg
Erschienen in
Journal of Neurology / Ausgabe 2/2016
Print ISSN: 0340-5354
Elektronische ISSN: 1432-1459
DOI
https://doi.org/10.1007/s00415-015-7983-1

Weitere Artikel der Ausgabe 2/2016

Journal of Neurology 2/2016 Zur Ausgabe

Leitlinien kompakt für die Neurologie

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Stuhltransfusion könnte Fortschreiten von Parkinson-Symptomen bremsen

03.05.2024 Parkinson-Krankheit Nachrichten

Kann eine frühzeitige Stuhltransplantation das Fortschreiten von Parkinson-Symptomen verlangsamen? Die Ergebnisse einer randomisierten Phase-2-Studie scheinen dafür zu sprechen.

Frühe Tranexamsäure-Therapie nützt wenig bei Hirnblutungen

02.05.2024 Hirnblutung Nachrichten

Erhalten Personen mit einer spontanen Hirnblutung innerhalb von zwei Stunden nach Symptombeginn eine Tranexamsäure-Therapie, kann dies weder die Hämatomexpansion eindämmen noch die Mortalität senken.

Sind Frauen die fähigeren Ärzte?

30.04.2024 Gendermedizin Nachrichten

Patienten, die von Ärztinnen behandelt werden, dürfen offenbar auf bessere Therapieergebnisse hoffen als Patienten von Ärzten. Besonders scheint das auf weibliche Kranke zuzutreffen, wie eine Studie zeigt.

Akuter Schwindel: Wann lohnt sich eine MRT?

28.04.2024 Schwindel Nachrichten

Akuter Schwindel stellt oft eine diagnostische Herausforderung dar. Wie nützlich dabei eine MRT ist, hat eine Studie aus Finnland untersucht. Immerhin einer von sechs Patienten wurde mit akutem ischämischem Schlaganfall diagnostiziert.

Update Neurologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.